Clinical trial

A Study of IBI3032 in Chinese Participants With Overweight or Obesity

Active, not recruiting · Phase 1 · 1 countries · Registry ID NCT07170319

Active, not recruitingPhase 1Interventional

What this study is about

This is a randomized, double-blind, placebo-controlled phase 1 clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple ascending doses of IBI3032 in participants with overweight or obesity. It is a multiple ascending dose study in participants with overweight or obesity during the 4-week treatment period.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to 65 Years

SexAll

Healthy volunteersAccepted

ConditionOverweight or Obesity

Full registry criteria

Inclusion Criteria: * Healthy male or females, as determined by medical history * Have safety laboratory results within normal reference ranges Exclusion Criteria: * Have known allergies toIBI3032， glucagon-like peptide-1 (GLP-1) analogs, related compounds * Abnormal electrocardiogram (ECG) at screening * Significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological or neurological disorders.

Treatments and study arms

IBI3032

Drug

IBI3032. Method of administration: oral, fasted administration.

placebo

Drug

Placebo (without active ingredients). Method of administration: oral, fasted administration.

Primary outcomes

Number of Participants with One Serious Adverse Event(s) Considered by the Investigator to be Related to Study DrugBaseline up to Day 43

A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module

Number of Participants with More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study DrugBaseline up to Day 43

A summary of other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module

Number of Participants with adverse events (AEs)An adverse event (AE) is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related.

Baseline up to Day 43

Study locations

1 locations were listed when this page was built. The first 40 are shown.

The Frist Affiliated Hospital of Anhui Medical University🇨🇳 Hefei, Anhui, China

Open map